Cannabis-based medicines for chronic neuropathic pain in adults
Mucke M, Phillips T, Radbruch L
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane review of 16 RCTs of cannabis-based medicines for chronic neuropathic pain.
Key Findings
Potential benefits were of low quality and may be outweighed by central nervous system adverse effects and withdrawals.
Conclusions
Cannabis-based medicines have limited, low-certainty benefit in chronic neuropathic pain.
Limitations
Short trials; high placebo response; unblinding likely.
Outcomes Measured
Potential benefits were of low quality and may be outweighed by central nervous system adverse effects.
Potential benefits were of low quality and may be outweighed by central nervous system adverse effects.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.